- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07947927
A Pragmatic Study of MRD-Guided Maintenance for Multiple Myeloma in Latin America
Applicability of MRD to Tailored Maintenance in Multiple Myeloma: A Pragmatic Prospective Multicenter Study in Latin America
This prospective, pragmatic, multicenter study aims to evaluate the clinical and quality-of-life outcomes of discontinuing maintenance therapy in newly diagnosed MM patients with sustained MRD negativity for two years. By implementing a structured active surveillance strategy with serial MRD and QoL assessments, this study seeks to determine whether treatment-free intervals can be safely achieved without compromising survival outcomes, while improving patient well-being and reducing financial burden.
If successful, this study will provide foundational evidence to support MRD-guided, individualized maintenance strategies in MM and will serve as a platform for future interventional trials in Latin America.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Multiple myeloma is a blood cancer that can require long-term maintenance treatment, even after a very good response to initial therapy. Although maintenance treatment can help control the disease, continuing it for many years may cause side effects, affect quality of life, and create financial burdens. Measurable residual disease (MRD) testing can detect very small amounts of myeloma cells that may remain after treatment.
This prospective, multicenter study in Latin America will evaluate a strategy of stopping maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved a complete or stringent complete response and have remained MRD-negative for at least two consecutive years while receiving maintenance therapy.
After maintenance therapy is discontinued, participants will be followed for 24 months through clinical assessments, MRD testing, and quality-of-life questionnaires every six months. Maintenance therapy will be restarted if MRD reappears or if clinical or biochemical criteria for disease relapse are met, according to the study protocol.
The main objective is to evaluate whether this strategy can be implemented safely and to measure the occurrence of MRD reappearance, disease relapse, or death within 24 months. Additional objectives include evaluating progression-free survival, overall survival, quality of life, time until maintenance therapy is restarted, and the feasibility of this approach across Latin American centers.
The study aims to generate evidence to help guide individualized maintenance treatment decisions for selected patients with multiple myeloma.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Yadith Karina Lopez Garcia, MD
- Telefoonnummer: +52 81 8675 6718
- E-mail: yadith.lopezgrc@uanl.edu.mx
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years at the time of enrollment.
- Diagnosis of newly diagnosed multiple myeloma according to International Myeloma Working Group (IMWG) criteria.
- Achievement of complete response (CR) or stringent complete response (sCR) following first-line therapy, with or without autologous hematopoietic cell transplantation (auto-HCT).
- Receipt of maintenance therapy for a minimum of 12 months prior to screening.
- Sustained measurable residual disease (MRD) negativity documented by next-generation flow cytometry (NGF assay EuroFlow-based or equivalent): MRD negativity confirmed on at least two consecutive bone marrow assessments, separated by a minimum of 12 months, with assessments performed during ongoing maintenance therapy.
- Negative functional imaging prior to maintenance discontinuation, defined as no evidence of metabolically active focal lesions on PET/CT, performed during screening.
- Absence of extramedullary disease at the time of study entry.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Ability to comply with study procedures, including serial MRD and quality-of-life assessments.
- Provision of written informed consent prior to any study-specific procedures.
Exclusion Criteria:
- Evidence of MRD positivity by NGF at any assessment during screening.
- PET/CT-positive lesions suggestive of active myeloma at screening.
- Biochemical or clinical relapse at the time of screening, as defined by IMWG criteria.
- Prior progression while receiving maintenance therapy.
- Any uncontrolled medical condition or comorbidity that, in the investigator's judgment, would compromise patient safety or protocol compliance.
- Inability or unwillingness to adhere to protocol-defined follow-up and surveillance procedures.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: MRD-Guided Maintenance Discontinuation and Active Surveillance
Eligible participants will discontinue maintenance therapy after meeting the protocol-defined criteria, including sustained measurable residual disease (MRD) negativity for at least two consecutive years and no evidence of active disease on PET/CT. Participants will undergo active surveillance for 24 months, with clinical assessments, MRD testing, and health-related quality-of-life evaluations every six months. If MRD reappears or clinical or biochemical disease relapse criteria are met, maintenance therapy will be reinitiated according to the study protocol. All participants will receive the same intervention strategy, as this is a single-arm study. |
The intervention consists of discontinuing maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved complete response or stringent complete response and sustained measurable residual disease (MRD) negativity for at least two consecutive years during maintenance therapy, with no evidence of active disease on PET/CT. Following discontinuation, participants will undergo active surveillance for 24 months, with clinical assessments, bone marrow MRD testing, and health-related quality-of-life evaluations every six months. MRD will be assessed using next-generation flow cytometry. Maintenance therapy will be reinitiated if MRD reappears or if clinical or biochemical disease relapse criteria are met, according to the study protocol. The strategy is evaluated prospectively in a single-arm, multicenter study across Latin America. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Strategy Failure Rate at 24 Months Following MRD-Guided Maintenance Discontinuation
Tijdsspanne: From maintenance discontinuation (baseline) through 24 months.
|
Strategy failure is defined as the first occurrence of any of the following events after maintenance discontinuation: (1) measurable residual disease (MRD) resurgence, defined as conversion from sustained MRD negativity to MRD positivity detected by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5); (2) clinical or biochemical relapse/progression according to IMWG criteria; or (3) death from any cause. The outcome will be measured as the proportion of participants experiencing at least one strategy failure event. |
From maintenance discontinuation (baseline) through 24 months.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Measurable Residual Disease-Free Survival (MRD-FS)
Tijdsspanne: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the first occurrence of MRD resurgence or death from any cause. MRD will be assessed using next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). MRD-FS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Treatment-Free Survival (TFS)
Tijdsspanne: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to re-initiation of maintenance therapy or death from any cause, whichever occurs first. TFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Progression-Free Survival (PFS)
Tijdsspanne: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to documented clinical or biochemical disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Overall Survival (OS)
Tijdsspanne: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to death from any cause. Overall survival will be estimated using the Kaplan-Meier method, with survival probabilities reported at 12 and 24 months. |
From maintenance discontinuation through 24 months.
|
|
Measurable Residual Disease (MRD) Resurgence Rate
Tijdsspanne: At months 6, 12, 18, and 24 after maintenance discontinuation.
|
Proportion of participants who convert from sustained MRD negativity to MRD positivity during follow-up, assessed by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). |
At months 6, 12, 18, and 24 after maintenance discontinuation.
|
|
Time to Maintenance Therapy Re-initiation
Tijdsspanne: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the re-initiation of maintenance therapy, regardless of whether treatment is restarted due to MRD resurgence, clinical or biochemical relapse, or investigator discretion. |
From maintenance discontinuation through 24 months.
|
|
Change From Baseline in Health-Related Quality of Life Assessed by EORTC QLQ-C30
Tijdsspanne: Baseline and months 6, 12, 18, and 24.
|
Changes in health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
|
Change From Baseline in Multiple Myeloma-Specific Quality of Life Assessed by EORTC QLQ-MY20
Tijdsspanne: Baseline and months 6, 12, 18, and 24.
|
Changes in multiple myeloma-specific health-related quality of life will be assessed using the EORTC QLQ-MY20 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Hemische en lymfatische ziekten
- Multipel myeloom
- Health Services Administration
- Kwaliteit van de gezondheidszorg
- Uitkomstbeoordeling, gezondheidszorg
- Uitkomst en procesbeoordeling, gezondheidszorg
- Waakzaam wachten
Andere studie-ID-nummers
- HE26-00024
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .